The new 300µL interlocked robotic arm machine (RAM) vial with 9mm thread finish from J G Finneran Associates based in Vineland, NJ, US is aimed at researchers tasked with managing a high number of chromatography sample vials in their laboratories.
Composed of a clear or amber Type I borosilicate glass, the vial and insert are fused together keeping the insert permanently in place. This enables accurate automated injection and eliminates contamination risk around the seam or space between the neck of the vial and the insert. The interlocked RAM vial arrives ready to use saving valuable time in the laboratory.
The vial has been designed to work in robotic arm autosamplers such as those available from Agilent Technologies and others. Robotic arms can easily grasp the 12mm x 32mm outer dimensions of the vial. Chromatography samples are contained in a clear Type I borosilicate glass 300µL conical tip insert. The interlocked RAM vial includes a marking spot, which can be written on with a #2 pencil. The vial is also available with a 9mm screw thread closure.
Interlocked RAM vial provides safe sample containment
For researchers managing a high number of chromatography sample vials
You may also like
Manufacturing
Patented device reinvents Solid Phase Extraction
Read moreBiotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Trending Articles
You may also like
Manufacturing
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Manufacturing
Why your coating process is less consistent than you think - and what to do about it
Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale